tretinoin

Overview

Tretinoin (all-trans retinoic acid, ATRA) is a retinoic acid receptor (RAR) agonist that promotes myeloid differentiation. It is the standard of care in acute promyelocytic leukemia (APL), where the PML-RARA fusion protein disrupts RAR signaling; ATRA restores differentiation and combined with arsenic trioxide or chemotherapy achieves cure rates exceeding 90%. It has also been evaluated as an adjunct to standard induction in other AML subtypes.

Evidence in the corpus

• Added to ICE induction (idarubicin+cytarabine+etoposide) in two of the three AMLSG intensive-therapy trial arms (AMLSG-07-04 and AML-HD98B) in 1540 adults with AML; study defined 11 genomic AML subgroups including the PML-RARA-defined APL subgroup (4%, n=60, HR 0.3) PMID:27276561

Resistance mechanisms

Cancer types (linked)

• AML

Sources

This page was processed by crosslinker on 2026-05-14.